Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9+ cancer stem cells in ulcerative colitis-related cancer

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 4, 2016, Pages 487-493

  Seishima, Ryo ^a   Okabayashi, Koji ^a   Nagano, Osamu ^a   Hasegawa, Hirotoshi ^a   Tsuruta, Masashi ^a   Shimoda, Masayuki ^a   Kameyama, Kaori ^a   Saya, Hideyuki ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; KI 67 ANTIGEN; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR CDX2; UVOMORULIN; CADHERIN; CD44 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; GASTROINTESTINAL AGENT; HYALURONIC ACID BINDING PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; ADENOCARCINOMA; CANCER STEM CELL; COLORECTAL TUMOR; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; CADHERINS; CDX2 TRANSCRIPTION FACTOR; CELL DIFFERENTIATION; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYALURONAN RECEPTORS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SULFASALAZINE;

EID: 84952900340     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.11.007     Document Type: Article

References (31)

1. [1] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420:6917 (2002), 860–867.
2. [2] Eaden, J.A., Abrams, K.R., Mayberry, J.F., The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:4 (2001), 526–535.
3. [3] Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F., Loguercio, C., Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121:11 (2007), 2381–2386.
4. [4] Waris, G., Ahsan, H., Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog, 5, 2006, 14.
5. [5] Pelicano, H., Carney, D., Huang, P., ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:2 (2004), 97–110.
6. [6] Jackson, A.L., Loeb, L.A., The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477:1–2 (2001), 7–21.
7. [7] Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19:3 (2011), 387–400.
8. [8] Nagano, O., Okazaki, S., Saya, H., Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32:44 (2013), 5191–5198.
9. [9] O'Brien, C.A., Pollett, A., Gallinger, S., Dick, J.E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:7123 (2007), 106–110.
10. [10] Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peshle, C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445:7123 (2007), 111–115.
11. [11] Choi, D., Lee, H.W., Hur, K.Y., Kim, J.J., Park, G.S., Jang, S.H., et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15:18 (2009), 2258–2264.
12. [12] Bendardaf, R., Elzagheid, A., Lamlum, H., Ristamaki, R., Collan, Y., Pyrhonen, S., E-cadherin. CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep 13:5 (2005), 831–835.
13. [13] Tanabe, K.K., Ellis, L.M., Saya, H., Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341:8847 (1993), 725–726.
14. [14] Mayer, B., Jauch, K.W., Gunthert, U., Figdor, C.G., Schildberg, F.W., Funke, I., et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 342:8878 (1993), 1019–1022.
15. [15] Miwa, T., Watanabe, A., Yamada, Y., Shino, Y., Yamada, T., Yamashita, J., et al. Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Cancer 77:1 (1996), 25–29.
16. [16] van Staa, T.P., Card, T., Logan, R.F., Leufkens, H.G., 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a Large Epidemiological Study. Gut 54:11 (2005), 1573–1578.
17. [17] Velayos, F.S., Terdiman, J.P., Walsh, J.M., Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:6 (2005), 1345–1353.
18. [18] Chen, R.S., Song, Y.M., Zhou, Z.Y., Tong, T., Li, Y., Fu, M., et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 28:4 (2009), 599–609.
19. [19] Gout, P.W., Buckley, A.R., Simms, C.R., Bruchovsky, N., Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)− cystine transporter: a new action for an old drug. Leukemia 15:10 (2001), 1633–1640.
20. [20] Lo, M., Wang, Y.Z., Gout, P.W., The x(c)− cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 215:3 (2008), 593–602.
21. [21] Brentnall, T.A., Crispin, D.A., Rabinovitch, P.S., Haggitt, R.C., Rubin, C.E., Stevens, A.C., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107 (1994), 369–378.
22. [22] Yin, J., Harpaz, N., Tong, Y., Huang, Y., Laurin, J., Greenwald, B.D., et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104 (1993), 1633–1639.
23. [23] Wada, T., Ishimoto, T., Seishima, R., Tsuchihashi, K., Yoshikawa, M., Oshima, H., et al. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci 104:10 (2013), 1323–1329.
24. [24] Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:2 (1998), 155–168.
25. [25] Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73:6 (2013), 1855–1866.
26. [26] Keiichiro, S., Masahiro, A., Reiji, K., Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial–mesenchymal transition. PNAS 109:20 (2012), 7776–7781.
27. [27] Mizoshita, T., Inada, K., Tsukamoto, T., Kodera, Y., Yamamura, Y., Hirai, T., et al. Expression of Cdx1 and Cdx2 mRNAs and relevance of this expression to differentiation in human gastrointestinal mucosa. Gastric Cancer 4:4 (2001), 185–191.
28. [28] Guo, R.J., Suh, E.R., Lynch, J.P., The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther 3:7 (2004), 593–601.
29. [29] Yanagisawa, N., Mikami, T., Mitomi, H., Saegusa, M., Koike, M., Okayasu, I., CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer 91:2 (2001), 408–416.
30. [30] Chen, S., Hou, J.H., Feng, X.Y., Zhang, X.S., Zhou, Z.W., Yun, J.P., et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol 107:8 (2013), 799–806.
31. [31] Watanabe, T., Konishi, T., Kishimoto, J., Kotake, K., Muto, T., Sugihara, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a Nationwide Japanese Study. Inflamm Bowel Dis 17:3 (2011), 802–808.